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ABSTRACT 
Association between the expression of ribosomal protein (RP) genes and cancer is widely known. More 
specifically, the extra-ribosomal functions of RPs have been linked to carcinogenesis. The ribosomal protein gene, 
eL14 has been reported to be associated with malignancy of the colorectum, albeit of mechanism yet unclear. Its 
expression in cells derived from different tissue origin of colorectal carcinoma (CRC) has never been explored. 
Therefore, this study aims to comparatively analyse the expression pattern of eL14 between two different CRC 
cell lines (DLD-1 and HCT116). It involved a conventional gene expression analysis, the Reverse-Transcriptase 
PCR (RT-PCR) assays. Products of RT-PCR assay were resolved via an agarose gel electrophoresis method, and 
band intensities of amplicons were documented and quantified using TotalLab Quant software. We observed 
differential expression patterns of eL14 between DLD-1 and HCT116 cells, but statistical analysis revealed 
insignificant differences. Therefore, the relevance of eL14 as a biomarker to distinguish between different 
colorectal cancer cells is suggestive but not conclusive.  
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Ribosomal protein (RP) genes are necessary and ubiquitous components of ribosome structures essential in the 
process of protein biosynthesis. Increasing evidences have also pointed to the linked between RPs many diseases, 
including cancer (Chen et al., 2016). In fact, aberrancies in ribosome biogenesis may be partly responsible for 
cancer and/or susceptibility to cancer (Ruggero & Pandolfi, 2003). Beyond ribosome-related context, the extra-
ribosomal roles of RPs have also been established, of which perturbation(s) of such roles has been linked to 
carcinogenesis also (Wang et al., 2014).  
 
Ribosomal protein eL14 is a member of the RPs for the large ribosomal subunit (60S) group. It is located at 
Chromosome 3, in the position of 3p22.1, and consists of 6 exons and 5 introns (Huang et al., 2006). eL14 contains 
a variable-length polyalanine tract that is encoded by a highly polymorphic trinucleotide repeat array (Shriver et 
al., 1998). Studies have demonstrated the down-regulated pattern of eL14 in lung and oral cancers (Shriver et al., 
1998), and oesophageal cancer (Huang et al., 2006). The eL14 gene lies with a genomic region (3p21) that has a 
high frequency of alteration (including translocation, deletion and allelic loss) that may contribute to the 
transcriptional loss. These are possible scenarios responsible for malignancy in lung and oral tissues (Shriver et 
al., 1998). Indeed, loss of heterozygosity (LOH) in eL14 is linked to lung and oral carcinomas (Shriver et al., 
1998). In the case of oesophageal cancer, genetic alteration and LOH in eL14 have been reported (Huang et al., 
2006). Besides these cancer types, eL14 has also been shown to be associated with hepatocellular carcinoma or 
liver cancer (Liu et al., 2007).  
 
To date, involvement or connection of eL14 to cancer of the colon and rectum region (colorectal carcinoma) has 
not established.  Prior to this study, expression analysis of eL14 in any cancer model of colorectal carcinoma 
(CRC) has not been reported in the literature. Therefore, this study is among the first exploration to investigate 











MATERIALS & METHODS 
 
Cell Culture 
Colorectal carcinoma cell lines used in the study were DLD-1 and HCT116. These commercially-available cell 
lines were procured from ATCC. DLD-1 was derived from a Stage C cancer tissue at the sigmoid colon of a 50-
year old male, and is a non-metastatic cell with moderate cellular differentiation (Dexter et al., 1981; Schneider et 
al., 2012). HCT116 is a human epithelial colorectal carcinoma cell line derived from a Stage D tumour at the 
ascending colon, and is poorly differentiated and metastatic (Brattain, Fine, Khaled, Thompson & Brattain, 1981; 
Wahab et al., 2017). All cell lines were grown at 37°C, 5% CO2, and 95% humidity until the confluent stage of 
70-90% before harvested for total RNA.  
 
RNA Extraction 
The TRIzol method (Chomczynski & Sacchi, 1987) was used for RNA extraction. Basically, monolayer cells in 
culture flask were rinsed with ice-cold PBS prior to the addition of 1ml TRIzol reagent. Then, the cells were gently 
scraped, and mechanically lysed by repeated pipetting before incubation for 5 min at room temperature. 
Subsequently, the lysate was transferred to a 1.5 ml sterile microcentrifuge tube, followed by the addition of 0.2 
ml chloroform. This mixture was thoroughly mixed by vortexing for 15 sec, and then incubated at room 
temperature for 3 minutes. Then, the homogenate was centrifuged at 12,000 rpm for 15 min at 4°C. The aqueous 
phase was transferred into a new 1.5 ml sterile microcentrifuge tube, followed by the addition of 0.5 ml 
isopropanol. This was incubated at room temperature for 10 min, and then centrifuged at 10,000 rpm at 4°C for 10 
min. The supernatant was removed, and the resulting RNA pellet was washed once with 1ml of 75% ethanol. It 
was air dried for 10 min, prior to dissolution 30 µl nuclease-free. The RNA solution was stored at -80°C until use. 
Quantity and quality check were carried out using spectrophotometric analysis.  
 
Reverse-transcription and Polymerase Chain Reaction 
Complementary DNA (cDNA) was synthesised using Moloney Murine Leukemia Virus Transcriptase (M MLV-
RT). Two microlitre of random primers was added to 2 µg of RNA sample in a sterile 1.5ml tube. Nuclease-free 
water was then added to make the total volume of 15 µl. The mixture was incubated for 5 min at 70°C, and cooled 
on ice for 1 min. Then 1.25 µl of 10mM dNTPs, 5 µl M-MLV 5X reaction buffer, 0.6 µl of Recombinant RNAsin® 
Ribonuclease Inhibitor and 1 µl of M-MLV RT were added. The tube was flicked gently to mix the solution. Then, 
nuclease-free water was added to make the total volume to 25 µl. This was incubated at 37°C for 60 min, and then 
at 70°C for 15 min. Polymerase Chain Reaction assay was carried out according to the protocol for GoTaq® 
Polymerase (Promega, USA). The primer pair for eL14 consists of the forward (5’- TTCTTCCTTCTCGCCTAA 
CG-3’) and reverse (5’-CCTCCTAACTCCAGCCTCAA-3’) primers, and the pair for GAPDH comprises 5’- 
AGATCATCAGCAATGCCTC-3’ and 5’-TACCAGGACATGAGCTTGAC-3’ as the forward and reverse 
primers, respectively. Expected amplicon size for eL14 and GAPDH is 877bp and 507bp, respectively. The 
GAPDH gene functioned as an internal control for consideration of the equalizing amount of loaded sample, and 
allowed normalisation of data among the test results. For each PCR test, the components included 0.5 ug of 
template DNA, 1X Green Go Taq® Flexi Buffer, 1.0 mM MgCl2, 0.2 mM dNTP mix, 0.4 µM each of the forward 
and reverse primers, and 1.25 U of Go Taq® Polymerase. Nuclease-free water was added to each mixture to a total 
volume of 25 µl. The thermal cycling conditions were initial denaturation at 95°C for 2 min, followed by 35 cycles 
of denaturation at 95°C for 30 sec, primers annealing (53°C for eL14, and 58°C for GAPDH) for 30 sec, and 
extension at 72°C for 1 min. A final extension of 5 min at 72°C was also included. PCR was done using a 
SensoQuest (Germany) PCR machine. The PCR products were resolved using agarose gel electrophoresis (AGE) 
method, and visualised using EtBr-stained gel on a UV transilluminator. Biological replicates were applied for 
each test.  
 
Data Analysis 
Band intensities of PCR products from AGE were measured using TotalLab Quant Software (TotalLab, USA) for 
the analysis of differential expression levels of both RPeL14 and GAPDH. The normalised value of each gene in 
each cell line was calculated based on the formula by Sim, Chee, Vasudevan, Ng and Chan (2018).  
 
Validation of relative quantification of gene expression patterns can be done using Paired Student’s t-test with a 
confidence interval of 95%. A significant difference was taken at p < 0.05. 
 
 







Observable transcript expression, as far as RT-PCR products, was detected for eL14 and GAPDH (internal 
control) in both DLD-1 and HCT116 cells (Figure 1). Eye-balling assessment (based on band intensities) revealed 
a general difference in the expression level of eL14 between DLD-1 and HCT116 cells. The expression is 




Figure 1. AGE analysis representation of RT-PCR assays of eL14 and GAPDH expression pattern 
in DLD-1 and HCT116 cell lines. Lanes 1 and 8 are eL14 in DLD-1 cells, Lanes 4 and 11 are 
GAPDH in DLD-1 cells, Lanes 2 and 9 are eL14 in HCT116 cells, Lanes 5 and 12 are GAPDH 
in HCT116 cells, Lanes 3 and 10 are negative controls for eL14, Lanes 6 and 13 are negative 
controls for GAPDH, and Lane 7 is the size marker, 1kb DNA ladder. Lanes 1 to 6, and Lanes 8 
to 13 represent Replicate 1 and 2, respectively. 
 
 
The band intensities of both eL14 and GAPDH in DLD-1 and HCT116 were documented and analysed using 
TotalLab Quant Software (TotalLab, USA). The result of both raw and processed data (normalised band intensities) 
are presented in Table 1. The normalised data of eL14 expression in both DLD-1 and HCT116 is illustrated in a bar 
chart (Figure 2). Based on the bar chart, the band intensity of RPeL14 in DLD-1 is observably higher than in 
HCT116. Statistical analysis via Student’s t-test was applied to the normalised band intensity data. The results 





Figure 2. Bar chart of the normalised band intensities of eL14 
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Table 1. Band intensities of eL14 and GAPDH (and the normalized value of eL14) for the CRC cell lines used. 
Cell lines Replicate 
Band Intensity Standard 
Deviation eL14 GAPDH Average GAPDH Normalised 
Normalised 
Average 
DLD-1 1 38228 34697 
38646 
42579 39857 3850 2 39937 41561 37135 





Our results indicate observable differential expression of eL14 between DLD1-1 and HCT116, but the difference 
is not statistically significant. Nevertheless, expression of eL14 in both CRC cell lines has been proven and reported 
for the first time here. Prior to this, its expression has been found in lung, oral (Shriver et al., 1998) and oesophageal 
carcinoma (Huang et al., 2006), of which was reportedly down-regulated in the diseased situation. In our case, the 
lack of availability of a normal cell lines for comparative limited our analysis to cancer cell lines. We were unable 
to infer whether eL14 is up- or down-regulated in CRC models/cases. Between CRC cell lines of different origin, 
cell types and stages, the expression of eL14 was initially observed to be different in level. However, this difference 
was not substantiated after a statistical analysis. Further studies, involving more different CRC cell lines will have 
to be carried out before any conclusion regarding the association of eL14 to CRC scenario can be inferred. More 
tellingly, a normal control is required to be comparatively analysed with a variety of CRC cell lines for the 
hypothesis of a connection between eL14 to CRC tumourigenesis to be accepted. A better model to be studied is, 
perhaps, actual tumours from CRC patients.  
Besides our study, another research involving eL14 expression in CRC cell lines (HCT116 and SW480) has been 
done by other members of our research team (Sim, Mutsamy & Teh, 2020). Our data here concurs with this other 
study, in that expression of eL14 is detected in CRC cell lines. Our data here indicated higher expression (albeit 
insignificant) of eL14 in cells (DLD-1) derived from an earlier stage (Stage C) of CRC compared to that (HCT116) 
from a more advanced stage (Stage D). In contrast, the findings by Sim et al. (2020) demonstrated a different 
scenario, whereby expressed transcripts of eL14 is significantly higher in a cell line (HCT116) derived from an 
advanced stage of CRC compared to that (SW480) that is from an early stage (Stage B) of the cancer. The 
inconsistency of expression trends in eL14 between all these studies suggests a comprehensive and simultaneous 
expression assay on many different CRC cell lines, together with relevant normal controls is warranted.  
In addition to more cell lines, future expression study should utilise the quantitative PCR strategy for a more 
accurate and sensitive assessment of gene expression activity. The use of conventional RT-PCR method entails 
inaccuracy due to the fact that it is limited to the evaluation of end-point PCR product quantity. Quantitative PCR, 
however, allows for real-time measurement of the amplification process. Naturally, immunohistochemical 
techniques on CRC tissues to detect and quantify eL14 expression would be an even better strategy for future study 




Expression of eL14 has been detected in two cell lines (HCT116 and DLD-1) derived from CRC tissues. The 
level of transcripts is observably higher in DLD-1 (from Stage C cancer) than HCT116 (from Stage D). 
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